318 related articles for article (PubMed ID: 30819358)
1. Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction.
Silvain J; Rakowski T; Lattuca B; Liu Z; Bolognese L; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimsky P; Miller D; Portal JJ; Collet JP; Vicaut E; Montalescot G; Dudek D;
J Am Coll Cardiol; 2019 Mar; 73(8):906-914. PubMed ID: 30819358
[TBL] [Abstract][Full Text] [Related]
2. Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study.
Montalescot G; Collet JP; Ecollan P; Bolognese L; Ten Berg J; Dudek D; Hamm C; Widimsky P; Tanguay JF; Goldstein P; Brown E; Miller DL; LeNarz L; Vicaut E;
J Am Coll Cardiol; 2014 Dec; 64(24):2563-2571. PubMed ID: 25524333
[TBL] [Abstract][Full Text] [Related]
3. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
[TBL] [Abstract][Full Text] [Related]
4. Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction: From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study.
Dudek D; Dziewierz A; Widimsky P; Bolognese L; Goldstein P; Hamm C; Tanguay JF; LeNarz L; Miller DL; Brown E; Ten Berg J; Montalescot G;
Am Heart J; 2015 Nov; 170(5):1025-1032.e2. PubMed ID: 26542513
[TBL] [Abstract][Full Text] [Related]
5. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.
Montalescot G; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; ten Berg JM; Miller DL; Costigan TM; Goedicke J; Silvain J; Angioli P; Legutko J; Niethammer M; Motovska Z; Jakubowski JA; Cayla G; Visconti LO; Vicaut E; Widimsky P;
N Engl J Med; 2013 Sep; 369(11):999-1010. PubMed ID: 23991622
[TBL] [Abstract][Full Text] [Related]
7. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38).
Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD
JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719
[TBL] [Abstract][Full Text] [Related]
8. Contemporary NSTEMI management: the role of the hospitalist.
Pollack CV; Amin A; Wang T; Deitelzweig S; Cohen M; Slattery D; Fanikos J; DiLascia C; Tuder R; Kaatz S
Hosp Pract (1995); 2020 Feb; 48(1):1-11. PubMed ID: 31815570
[TBL] [Abstract][Full Text] [Related]
9. The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study.
Effron MB; Wang TY; Fonarow GC; Henry TD; Zettler ME; Baker BA; McCoy LA; Peterson ED
Catheter Cardiovasc Interv; 2018 Feb; 91(2):242-250. PubMed ID: 28988425
[TBL] [Abstract][Full Text] [Related]
10. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P;
Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465
[TBL] [Abstract][Full Text] [Related]
11. Predictors of bleeding in patients with acute coronary syndromes treated with prasugrel.
Widimsky P; Motovska Z; Bolognese L; Dudek D; Hamm C; Tanguay JF; Ten Berg J; Brown E; LeNarz L; Miller DL; Montalescot G;
Heart; 2015 Aug; 101(15):1219-24. PubMed ID: 26060122
[TBL] [Abstract][Full Text] [Related]
12. Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction.
Koskinas KC; Zanchin T; Klingenberg R; Gencer B; Temperli F; Baumbach A; Roffi M; Moschovitis A; Muller O; Tüller D; Stortecky S; Mach F; Lüscher TF; Matter CM; Pilgrim T; Heg D; Windecker S; Räber L
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654204
[TBL] [Abstract][Full Text] [Related]
13. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489
[TBL] [Abstract][Full Text] [Related]
14. COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions: Rationale and design of the COMPARE CRUSH trial.
Vlachojannis GJ; Vogel RF; Wilschut JM; Lemmert ME; Delewi R; Diletti R; van Vliet R; van der Waarden N; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
Am Heart J; 2020 Jun; 224():10-16. PubMed ID: 32272255
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
16. An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Wilcox R; Iqbal K; Costigan T; Lopez-Sendon J; Ramos Y; Widimsky P
Curr Med Res Opin; 2014 Nov; 30(11):2193-205. PubMed ID: 25025610
[TBL] [Abstract][Full Text] [Related]
17. Impact of body mass index on clinical outcome among elderly patients with acute coronary syndrome treated with percutaneous coronary intervention: Insights from the ELDERLY ACS 2 trial.
De Luca G; Verdoia M; Savonitto S; Ferri LA; Piatti L; Grosseto D; Morici N; Bossi I; Sganzerla P; Tortorella G; Cacucci M; Ferrario M; Murena E; Sibilio G; Tondi S; Toso A; Bongioanni S; Ravera A; Corrada E; Mariani M; Di Ascenzo L; Petronio AS; Cavallini C; Vitrella G; Antonicelli R; Rogacka R; De Servi S;
Nutr Metab Cardiovasc Dis; 2020 May; 30(5):730-737. PubMed ID: 32127336
[TBL] [Abstract][Full Text] [Related]
18. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Montalescot G; Wiviott SD; Braunwald E; Murphy SA; Gibson CM; McCabe CH; Antman EM;
Lancet; 2009 Feb; 373(9665):723-31. PubMed ID: 19249633
[TBL] [Abstract][Full Text] [Related]
19. Nonculprit Lesion Myocardial Infarction Following Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome.
Scirica BM; Bergmark BA; Morrow DA; Antman EM; Bonaca MP; Murphy SA; Sabatine MS; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2020 Mar; 75(10):1095-1106. PubMed ID: 32164882
[TBL] [Abstract][Full Text] [Related]
20. Safety of the primary percutaneous coronary intervention strategy combining pre-hospital prasugrel, enoxaparin and in-hospital bivalirudin in acute ST-segment elevation myocardial infarction.
Viikilä J; Nieminen T; Tierala I; Laine M
BMC Cardiovasc Disord; 2016 Jul; 16(1):154. PubMed ID: 27475059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
